Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Island Pharmaceuticals Limited	
ABN	48 641 183 842	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Jason Carroll
Date of last notice	3 July 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder)	N/A
Date of change	24 July 2025
No. of securities held prior to change	30,975,750 - fully paid ordinary shares
	974,930 options exercisable at \$0.07 expiring 4 December 2025
	974,931 options exercisable at \$0.07 expiring 4 December 2026
Class	ORDINARY FULLY PAID SHARES
Number acquired	124,250
Number disposed	NIL
Value/Consideration	\$21,122
No. of securities held after change	31,100,000 - fully paid ordinary shares
	974,930 options exercisable at \$0.07 expiring 4 December 2025
	974,931 options exercisable at \$0.07 expiring 4 December 2026
Nature of change	on-market purchases

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

^{*} See <u>chapter 19</u> for defined terms. 01/01/2011 Appendix 3Y Page 1

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - *Closed period

Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See <u>chapter 19</u> for defined terms. 01/01/2011 Appendix 3Y Page 2